News

Video

Fixed-Duration Acalabrutinib plus Venetoclax With or Without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Dr. Alan Skarbnik discusses interim findings from the Phase 3 AMPLIFY trial, highlighting the efficacy and safety of fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, compared to chemoimmunotherapy for treatment-naive chronic lymphocytic leukemia.

Video Player is loading.
Current Time 0:00
Duration 24:00
Loaded: 0%
Stream Type LIVE
Remaining Time 24:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected